Biotech 365

Main menu

Skip to primary content
Skip to secondary content
  • Biotech 365
    • Contact
    • Offers
  • Biotech Companies
  • Database researchers
    • BioLeads
  • BioMarketplace
  • Biotech Jobs
  • Biopharma News

Tag Archives: engineered T cell receptor

Adaptimmune – engineered, increased affinity T cell receptors

Posted on 2015-02-22 by Biotech365

Adaptimmune is focused on T cells to target and destroy cancer by using engineered, increased affinity T cell receptors (TCRs) as a means of strengthening natural patient T cell responses.

Adaptimmune – engineered, increased affinity T cell receptors

adaptimmune Continue reading →

Posted in Biotech Companies, Biotech Companies UK, Biotech Companies USA | Tagged Adaptimmune, Adaptimmune - engineered, Ali Behbahani, autologous T cell therapies, autologous T cell therapy, Avidex, Bent Jakobsen, David Mott, disulfide bond, Elliott Sigal, engineered, engineered T cell receptor, engineered T cell receptors, engineered TCR, engineered TCRs, epitope, epitopes, GlaxoSmithKline, GSK, Gwendolyn Binder-Scholl, Helen Tayton-Martin, HLA, Ian Laing, Immunocore, Immunocore Ltd, increased affinity T cell receptor, increased affinity T cell receptors, James Noble, Jonathan Knowles, MediGene, molecular fingerprint, NY-ESO-1, Peter Thompson, T cell receptor, T Cell Receptors, T cell therapies, T cell therapy, T cells, T-cell, TCR, TCRs
Contact                       Offers                      
Proudly powered by WordPress